Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Return on Capital Employed for 5 consecutive years, with 0.35% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 1.0% to 0.35% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.35% through Dec 2025, down 1.0% year-over-year, with the annual reading at 0.31% for FY2025, 14.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.35% at 4D Molecular Therapeutics, up from 0.56% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.21% in Q2 2021, with the low at 0.56% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.34%, with a median of 0.34% recorded in 2024.
  • The sharpest move saw Return on Capital Employed grew 21bps in 2024, then fell -27bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.25% in 2021, then crashed by -70bps to 0.43% in 2022, then grew by 21bps to 0.34% in 2023, then increased by 0bps to 0.34% in 2024, then dropped by -4bps to 0.35% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.35%, 0.56%, and 0.48% for Q4 2025, Q3 2025, and Q2 2025 respectively.